Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Guilhot

Showing results (111-120 of 154) with videos related to

Pageof 16
Sort By:
Annals of Internal Medicine|October 1, 1996
Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemiaM W Kattan, Y Inoue, F J Giles, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary resultsF Guilhot, J P Lamagnère, J L Harousseau, et al.
Annals of Hematology|May 6, 2004
Priming with GM-CSF for acute myelogenous leukemia (AML): GOELAM dataF Witz, J L Harousseau, F Guilhot, et al.
Blood|June 1, 1992
Double-intensive therapy in high-risk multiple myelomaJ L Harousseau, N Milpied, J P Laporte, et al.
Leukemia|February 1, 1993
Cytogenetic heterogeneity in t(11;19) acute leukemia: clinical, hematological and cytogenetic analyses of 48 patients--updated published cases and 16 new observationsJ L Huret, A Brizard, R Slater, et al.
Seminars in Hematology|February 4, 2003
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapyJ Hasford, M Pfirrmann, R Hehlmann, et al.
Leukemia|July 4, 2008
Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemiaA Shimoni, M Leiba, M Schleuning, et al.
Presse Medicale (Paris, France : 1983)|November 25, 1989
[Treatment of localized forms of Hodgkin's disease with 3 courses of chemotherapy (ABVD-MP) in combination with wide focal and prophylactic lumbo-splenic radiotherapy. The POF 81/12 protocol]B Desablens, J M Tourani, P Casassus, et al.
Biochemical and Biophysical Research Communications|July 5, 2005
Osteopontin is upregulated by BCR-ABLS Flamant, T Kortulewski, A Dugray, et al.
The New England Journal of Medicine|July 24, 1997
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study GroupF Guilhot, C Chastang, M Michallet, et al.
Pageof 16

Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
Annals of Internal Medicine|October 1, 1996
Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemiaM W Kattan, Y Inoue, F J Giles, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary resultsF Guilhot, J P Lamagnère, J L Harousseau, et al.
Annals of Hematology|May 6, 2004
Priming with GM-CSF for acute myelogenous leukemia (AML): GOELAM dataF Witz, J L Harousseau, F Guilhot, et al.
Blood|June 1, 1992
Double-intensive therapy in high-risk multiple myelomaJ L Harousseau, N Milpied, J P Laporte, et al.
Leukemia|February 1, 1993
Cytogenetic heterogeneity in t(11;19) acute leukemia: clinical, hematological and cytogenetic analyses of 48 patients--updated published cases and 16 new observationsJ L Huret, A Brizard, R Slater, et al.
Seminars in Hematology|February 4, 2003
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapyJ Hasford, M Pfirrmann, R Hehlmann, et al.
Leukemia|July 4, 2008
Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemiaA Shimoni, M Leiba, M Schleuning, et al.
Presse Medicale (Paris, France : 1983)|November 25, 1989
[Treatment of localized forms of Hodgkin's disease with 3 courses of chemotherapy (ABVD-MP) in combination with wide focal and prophylactic lumbo-splenic radiotherapy. The POF 81/12 protocol]B Desablens, J M Tourani, P Casassus, et al.
Biochemical and Biophysical Research Communications|July 5, 2005
Osteopontin is upregulated by BCR-ABLS Flamant, T Kortulewski, A Dugray, et al.
The New England Journal of Medicine|July 24, 1997
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study GroupF Guilhot, C Chastang, M Michallet, et al.
Pageof 16